Biogen Drug Shows Promise in Phase 2 Cutaneous Lupus Trial
Litifilimab achieved clear or almost clear skin in 14.7% of patients at Week 16 versus 2.9% on placebo in...
eClinical Tech News
Brepocitinib VALOR Trial Shows Positive Dermatomyositis Data
In the Phase 3 VALOR trial (n=241), brepocitinib 30 mg once-daily delivered a 15.3-point greater improvement in mean Total...
MoonLake Reveals New Sonelokimab HS Phase 3 Trial Results
At Week 40 in the Phase 3 VELA program for moderate-to-severe hidradenitis suppurativa (HS), sonelokimab achieved a 62% HiSCR75...
LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial
Phase 2 results for LB-102 showed statistically significant reductions in PANSS total score across all doses with onset by...
BEAM-302 Trial Shows Compelling Data for AATD Treatment
Beam’s Phase 1/2 readout for BEAM-302 in severe alpha-1 antitrypsin deficiency (AATD) delivered clean, quantitative signals: at the 60...
Patient Dosing Begins in Promising Phase II LSALT Peptide Trial
No drug-related adverse events have been assessed to date in Arch Biopartners’ Phase II trial of LSALT peptide for...
Hutchmed Starts Phase III Trial for B-Cell Lymphoma in China
A randomized, double-blind Phase II study of HMPL-760 plus R-GemOx in relapsed/refractory DLBCL reportedly improved ORR, CRR, PFS, and...
Beyond Cancer UNO Trial: Early Data Suggests Safety, Activity
Seven of ten patients remained alive 19–37 months after a single intratumoral injection of ultra‑high concentration nitric oxide (UNO)...
Rhythm Announces Topline Results for Phase 3 EMANATE Trial
EMANATE, a global Phase 3 study of setmelanotide across four heterozygous MC4R-pathway genetic subgroups, missed its primary endpoint of...
Transcon CNP Shows Durable Benefits in Achondroplasia Study
At Week 104 of the pivotal ApproaCH trial in children with achondroplasia, once-weekly TransCon CNP (navepegritide) maintained gains in...